AroCell announces today a new collaboration with the University of Rome la Sapienza to evaluate the role of TK1 and PSA as response biomarkers after hormone treatment in castration-resistant prostate cancer patients.
In the study TK1 protein levels will be measured in serum samples using AroCell TK 210 ELISA. Serum samples will be collected from 50 patients with an advanced metastatic prostate cancer diagnosis and 40 healthy controls. TK1 and PSA will be measured at the time of the diagnosis and 1, 3, and 6 months after the start of treatment. The objective is to help clinicians obtain more information by measuring the TK1 as a responsive biomarker in castration-resistant metastatic prostate cancer patients treated with hormone therapy.
The study will be executed in collaboration with Dr. Emanuela Anastasi at the Department of Molecular Medicine, University of Rome la Sapienza, Italy.
“We are excited to collaborate with University of Rome la Sapienza”, says Michael Brobjer, CEO of AroCell. “The AroCell TK 210 ELISA kit is a cost-efficient way to improve the monitoring of subjects with prostate cancer via a simple blood test, reducing costs and morbidity and improving patient’s quality of life”.